TSHA: Taysha Gene Therapies, Inc. Common Stock Company Profile & Statistics

Taysha Gene Therapies, Inc. Common Stock Profile

About

Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.

Info & Links

CEO

Sean Nolan

Headquarters

3000 Pegasus Park Dr. Ste 1430
DALLAS, TX 75247, UNITED STATES

Auditor

Deloitte & Touche LLP

Share holders

Employees

Taysha Gene Therapies, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

1.19B

Enterprise Value

921.32M

Enterprise Value/EBITDA(ttm)

-9.92

Price to Earnings Ratio(ttm)

Price to Sales(ttm)

160.35

Price to Book(mrq)

5.22

Price to Cash(ytd)

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-1123.94%

Profit Margin(ttm)

-1161.34%

Return on Equity(ttm)

-78.44%

Return on Invested Capital(ttm)

-66.99%

Return on Assets(ttm)

-44.82%

Income Statement

Revenue(ttm)

8.10M

Revenue Per Share(ttm)

0.03

Gross Profit(ttm)

8.10M

EBITDA(ttm)³

-92.85M

Net Income Available to Common(ttm)

-92.72M

Diluted EPS(ttm)

-0.34

Share Statistics

Beta (5Y Monthly)

0.99

52-Week Change

117.66%

S&P 500 52-Week Change

18.10%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

272.79M

Dividend Yield

0.00%

Float⁴

262.48M

% Held by Insiders

3.78%

% Held by Institutions

77.70%

Balance Sheet

Total Cash(mrq)

313.21M

Total Cash Per Share(mrq)

1.15

Total Debt(mrq)

41.05M

Total Debt/Equity(mrq)

16.50%

Current Ratio(mrq)

12.48%

Quick Ratio(mrq)

12.48%

Book Value Per Share(mrq)

0.91

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.14

Free Cash Flow(ytd)

-42.58M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

TSHA

Taysha Gene Therapies, Inc. Common Stock